Cell therapy for end-stage liver disease: Current state and clinical challenge
Abstract. Liver disease involves a complex interplay of pathological processes, including inflammation, hepatocyte necrosis, and fibrosis. End-stage liver disease (ESLD), such as liver failure and decompensated cirrhosis, has a high mortality rate, and liver transplantation is the only effective tre...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2024-12-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000003332 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846118849014923264 |
|---|---|
| author | Lin Zhang Yuntian Deng Xue Bai Xiao Wei Yushuang Ren Shuang Chen Hongxin Deng Yanjie Yin |
| author_facet | Lin Zhang Yuntian Deng Xue Bai Xiao Wei Yushuang Ren Shuang Chen Hongxin Deng Yanjie Yin |
| author_sort | Lin Zhang |
| collection | DOAJ |
| description | Abstract. Liver disease involves a complex interplay of pathological processes, including inflammation, hepatocyte necrosis, and fibrosis. End-stage liver disease (ESLD), such as liver failure and decompensated cirrhosis, has a high mortality rate, and liver transplantation is the only effective treatment. However, to overcome problems such as the shortage of donor livers and complications related to immunosuppression, there is an urgent need for new treatment strategies that need to be developed for patients with ESLD. For instance, hepatocytes derived from donor livers or stem cells can be engrafted and multiplied in the liver, substituting the host hepatocytes and rebuilding the liver parenchyma. Stem cell therapy, especially mesenchymal stem cell therapy, has been widely proved to restore liver function and alleviate liver injury in patients with severe liver disease, which has contributed to the clinical application of cell therapy. In this review, we discussed the types of cells used to treat ESLD and their therapeutic mechanisms. We also summarized the progress of clinical trials around the world and provided a perspective on cell therapy. |
| format | Article |
| id | doaj-art-e5d9d4666e274df888ed14338160c81b |
| institution | Kabale University |
| issn | 0366-6999 2542-5641 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj-art-e5d9d4666e274df888ed14338160c81b2024-12-17T09:29:14ZengWolters KluwerChinese Medical Journal0366-69992542-56412024-12-01137232808282010.1097/CM9.0000000000003332202412050-00005Cell therapy for end-stage liver disease: Current state and clinical challengeLin Zhang0Yuntian Deng1Xue Bai2Xiao Wei3Yushuang Ren4Shuang Chen5Hongxin Deng6Yanjie YinDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaAbstract. Liver disease involves a complex interplay of pathological processes, including inflammation, hepatocyte necrosis, and fibrosis. End-stage liver disease (ESLD), such as liver failure and decompensated cirrhosis, has a high mortality rate, and liver transplantation is the only effective treatment. However, to overcome problems such as the shortage of donor livers and complications related to immunosuppression, there is an urgent need for new treatment strategies that need to be developed for patients with ESLD. For instance, hepatocytes derived from donor livers or stem cells can be engrafted and multiplied in the liver, substituting the host hepatocytes and rebuilding the liver parenchyma. Stem cell therapy, especially mesenchymal stem cell therapy, has been widely proved to restore liver function and alleviate liver injury in patients with severe liver disease, which has contributed to the clinical application of cell therapy. In this review, we discussed the types of cells used to treat ESLD and their therapeutic mechanisms. We also summarized the progress of clinical trials around the world and provided a perspective on cell therapy.http://journals.lww.com/10.1097/CM9.0000000000003332 |
| spellingShingle | Lin Zhang Yuntian Deng Xue Bai Xiao Wei Yushuang Ren Shuang Chen Hongxin Deng Yanjie Yin Cell therapy for end-stage liver disease: Current state and clinical challenge Chinese Medical Journal |
| title | Cell therapy for end-stage liver disease: Current state and clinical challenge |
| title_full | Cell therapy for end-stage liver disease: Current state and clinical challenge |
| title_fullStr | Cell therapy for end-stage liver disease: Current state and clinical challenge |
| title_full_unstemmed | Cell therapy for end-stage liver disease: Current state and clinical challenge |
| title_short | Cell therapy for end-stage liver disease: Current state and clinical challenge |
| title_sort | cell therapy for end stage liver disease current state and clinical challenge |
| url | http://journals.lww.com/10.1097/CM9.0000000000003332 |
| work_keys_str_mv | AT linzhang celltherapyforendstageliverdiseasecurrentstateandclinicalchallenge AT yuntiandeng celltherapyforendstageliverdiseasecurrentstateandclinicalchallenge AT xuebai celltherapyforendstageliverdiseasecurrentstateandclinicalchallenge AT xiaowei celltherapyforendstageliverdiseasecurrentstateandclinicalchallenge AT yushuangren celltherapyforendstageliverdiseasecurrentstateandclinicalchallenge AT shuangchen celltherapyforendstageliverdiseasecurrentstateandclinicalchallenge AT hongxindeng celltherapyforendstageliverdiseasecurrentstateandclinicalchallenge AT yanjieyin celltherapyforendstageliverdiseasecurrentstateandclinicalchallenge |